TR199901941T2 - Ampa resept�r�n�n etkinli�ini art�ran benzofurazan bile�ikleri. - Google Patents

Ampa resept�r�n�n etkinli�ini art�ran benzofurazan bile�ikleri.

Info

Publication number
TR199901941T2
TR199901941T2 TR1999/01941T TR9901941T TR199901941T2 TR 199901941 T2 TR199901941 T2 TR 199901941T2 TR 1999/01941 T TR1999/01941 T TR 1999/01941T TR 9901941 T TR9901941 T TR 9901941T TR 199901941 T2 TR199901941 T2 TR 199901941T2
Authority
TR
Turkey
Prior art keywords
ampa
resept
ikleri
etkinli
benzofurazan
Prior art date
Application number
TR1999/01941T
Other languages
English (en)
Turkish (tr)
Inventor
A. Rogers Gary
M. Marrs Christopher
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of TR199901941T2 publication Critical patent/TR199901941T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Luminescent Compositions (AREA)
TR1999/01941T 1997-02-13 1998-02-13 Ampa resept�r�n�n etkinli�ini art�ran benzofurazan bile�ikleri. TR199901941T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/800,108 US6110935A (en) 1997-02-13 1997-02-13 Benzofurazan compounds for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
TR199901941T2 true TR199901941T2 (xx) 1999-12-21

Family

ID=25177504

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/01941T TR199901941T2 (xx) 1997-02-13 1998-02-13 Ampa resept�r�n�n etkinli�ini art�ran benzofurazan bile�ikleri.

Country Status (24)

Country Link
US (3) US6110935A (cg-RX-API-DMAC10.html)
EP (2) EP0960105B1 (cg-RX-API-DMAC10.html)
JP (1) JP4446023B2 (cg-RX-API-DMAC10.html)
KR (1) KR100544295B1 (cg-RX-API-DMAC10.html)
CN (1) CN1085206C (cg-RX-API-DMAC10.html)
AT (2) ATE266649T1 (cg-RX-API-DMAC10.html)
AU (1) AU737802C (cg-RX-API-DMAC10.html)
BR (1) BR9807333B1 (cg-RX-API-DMAC10.html)
CA (1) CA2279319C (cg-RX-API-DMAC10.html)
CZ (1) CZ299765B6 (cg-RX-API-DMAC10.html)
DE (2) DE69823803T2 (cg-RX-API-DMAC10.html)
DK (2) DK1428534T3 (cg-RX-API-DMAC10.html)
ES (2) ES2264078T3 (cg-RX-API-DMAC10.html)
GB (1) GB2325225B (cg-RX-API-DMAC10.html)
HU (1) HUP0002303A3 (cg-RX-API-DMAC10.html)
ID (1) ID22342A (cg-RX-API-DMAC10.html)
IL (1) IL131200A (cg-RX-API-DMAC10.html)
NO (1) NO318935B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ336980A (cg-RX-API-DMAC10.html)
PL (1) PL199135B1 (cg-RX-API-DMAC10.html)
PT (2) PT1428534E (cg-RX-API-DMAC10.html)
RU (1) RU2189984C2 (cg-RX-API-DMAC10.html)
TR (1) TR199901941T2 (cg-RX-API-DMAC10.html)
WO (1) WO1998035950A1 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188837B (cg-RX-API-DMAC10.html) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
AU2002366756A1 (en) * 2001-12-20 2003-07-09 Alangudi Sankaranarayanan Use of benzofuroxan derivatives as antiplatelet agents
PL378366A1 (pl) * 2003-01-13 2006-04-03 Cortex Pharmaceuticals, Inc. Sposób leczenia osłabienia funkcji poznawczych spowodowanego deprywacją snu i stresem
PT1636215E (pt) * 2003-05-23 2008-04-29 Basilea Pharmaceutica Ag Furazanobenzimidazoles
ATE556710T1 (de) * 2004-01-26 2012-05-15 Cortex Pharma Inc Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren
BRPI0716375A2 (pt) * 2006-08-31 2013-10-15 Univ Alberta Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito...
CA2674321A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
ZA200904826B (en) * 2007-01-03 2010-09-29 Cortex Pharma Inc 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
JP5694765B2 (ja) * 2007-05-17 2015-04-01 コーテックス ファーマシューティカルズ, インコーポレイテッド グルタミン酸作動性シナプス反応を増強するための二置換アミド
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
ES2560095T3 (es) 2007-08-10 2016-02-17 Cortex Pharmaceuticals, Inc. Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
WO2010087980A2 (en) * 2009-02-02 2010-08-05 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory depression
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
AU2012225784B2 (en) 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
CN102633731B (zh) * 2012-03-13 2014-04-30 四川大学华西医院 6-喹喔啉甲酸酰胺化合物、制备方法和应用
KR101421032B1 (ko) * 2012-12-28 2014-07-22 주식회사 레고켐 바이오사이언스 (2-메틸-1-(3-메틸벤질)-1H-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
EP3311842A1 (en) 2013-06-13 2018-04-25 VeroScience LLC Compositions and methods for treating metabolic disorders
EP3436021B1 (en) 2016-03-29 2026-07-29 RespireRx Pharmaceuticals, Inc. Compositions comprising low impact ampakines for treating attention deficit disorders
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
FR2499991A1 (fr) * 1981-02-19 1982-08-20 Sandoz Sa Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
US4420485A (en) * 1982-09-29 1983-12-13 Hoechst-Roussel Pharmaceuticals Inc. 1'-[3-(1,2-Benzisoxazol-3-yl) proply]spiro[benzofuran-2(3H),3' or 4'-piperidines or 3'-pyrrolidines]
SU1657189A1 (ru) * 1988-05-23 1991-06-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ коррекции апато-абулических состо ний при шизофрении
SU1587050A1 (ru) * 1988-12-23 1990-08-23 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Производные (7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амина в качестве промежуточных продуктов в синтезе 2-[(7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амино]-5-бром-N-(4-хлорфенил)бензамида, обладающего антигельминтной активностью
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
DE69331761T2 (de) * 1992-07-24 2002-09-12 The Regents Of The University Of California, Oakland Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen
ATE174915T1 (de) * 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response

Also Published As

Publication number Publication date
NO993768L (no) 1999-09-23
NZ336980A (en) 2000-08-25
NO993768D0 (no) 1999-08-04
GB2325225B (en) 1999-03-03
DE69834590D1 (de) 2006-06-22
BR9807333B1 (pt) 2011-10-18
PT960105E (pt) 2004-09-30
JP2001512459A (ja) 2001-08-21
PL335058A1 (en) 2000-03-27
CZ279599A3 (cs) 2000-01-12
KR20000071082A (ko) 2000-11-25
EP1428534B1 (en) 2006-05-17
CA2279319A1 (en) 1998-08-20
DK0960105T3 (da) 2004-08-30
JP4446023B2 (ja) 2010-04-07
NO318935B1 (no) 2005-05-30
HUP0002303A2 (hu) 2001-04-28
DE69834590T2 (de) 2007-04-26
HUP0002303A3 (en) 2002-09-30
EP0960105A1 (en) 1999-12-01
AU6159998A (en) 1998-09-08
IL131200A0 (en) 2001-01-28
PT1428534E (pt) 2006-07-31
GB2325225A (en) 1998-11-18
US6730677B2 (en) 2004-05-04
US6313115B1 (en) 2001-11-06
DK1428534T3 (da) 2006-06-12
RU2189984C2 (ru) 2002-09-27
CA2279319C (en) 2008-08-05
ATE266649T1 (de) 2004-05-15
ES2221152T3 (es) 2004-12-16
US20020055508A1 (en) 2002-05-09
US6110935A (en) 2000-08-29
ATE326221T1 (de) 2006-06-15
CN1247534A (zh) 2000-03-15
PL199135B1 (pl) 2008-08-29
EP0960105B1 (en) 2004-05-12
AU737802C (en) 2005-05-12
ID22342A (id) 1999-09-30
CZ299765B6 (cs) 2008-11-19
DE69823803T2 (de) 2005-04-14
IL131200A (en) 2005-06-19
GB9809221D0 (cg-RX-API-DMAC10.html) 1998-07-01
DE69823803D1 (de) 2004-06-17
CN1085206C (zh) 2002-05-22
WO1998035950A1 (en) 1998-08-20
EP1428534A1 (en) 2004-06-16
GB2325225A8 (en) 1999-02-17
ES2264078T3 (es) 2006-12-16
AU737802B2 (en) 2001-08-30
KR100544295B1 (ko) 2006-01-23
BR9807333A (pt) 2000-04-18

Similar Documents

Publication Publication Date Title
DK0960105T3 (da) Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet
Machado Neurotransmission of the cardiovascular reflexes in the nucleus tractus solitarii of awake rats
Levy et al. Distinct sensitizing effects of the cAMP‐PKA second messenger cascade on rat dural mechanonociceptors
TR200002617T2 (tr) Aril ve heteroaril sübstitüentli heterosiklik üreler kullanılarak RAF kinazın inhibe edilmesi
TR200003801T2 (tr) Acı hafifletmek için deri üstü kompozisyonlar ve yöntemler
TR200100874T2 (tr) Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
TR199901173T2 (xx) Canl�larda glutamat anormalli�inin tedavisi ve n�ronal aktivitenin d�zenlenmesi i�in y�ntemler ve NAALADase bile�imleri.
DE60131730D1 (de) Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden
DE602004017494D1 (de) Inhibitoren von p-38-kinase
ATE451362T1 (de) Salze von liponsaürederivaten und deren verwendung bei der behandlung von krankheiten
Takeda et al. Intracellular Zn2+ signaling in the dentate gyrus is required for object recognition memory
EP1678096A4 (en) LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHOD OF USE THEREOF
ATE282625T1 (de) Gaba-c-rezeptor-antagonisten zur stimulation des erinnerungsvermögens
DE69418689D1 (de) Nitrone verwendbar zum abfangen von freien radikalen
Bernhard Distribution of internuncial activity in a multineuron reflex chain
ATE520653T1 (de) Verbindungen, die den durch dna-schädigung induzierten g2-checkpoint des zellzyklus stilllegen und/oder die antikrebswirkung von dna- schädigenden behandlungen erhöhen
Arnetz et al. Effects from 884 MHz mobile phone radiofrequency on brain electrophysiology, sleep, cognition, and well-being
Stevenson et al. Group Ia afferents likely contribute to short-latency interlimb reflexes in the human biceps femoris muscle
Puckett IDENTIFICATION AND CHARACTERIZATION OF CALCIUM UPTAKE AND CALCIUM RELEASE ACTIVITIES IN A PURIFIED DISC FRACTION ISOLATED FROM RODS OF BOVINE RETINA (TRANSDUCTION, VISION, GUANOSINC 3, 5'-CYCLIC MONOPHOSPHATE)
DE60329536D1 (de) Verfahren zur linderung von umweltbedingtem stress durch oxidationsmittel und regulierung vorteilhafter gene